Sökning: WFRF:(van der Schaaf Rene J) > Bioresorbable Scaff...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04407naa a2200481 4500 | |
001 | oai:DiVA.org:uu-342873 | |
003 | SwePub | |
008 | 180223s2017 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3428732 URI |
024 | 7 | a https://doi.org/10.1056/NEJMoa16149542 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Wykrzykowska, Joanna J4 aut |
245 | 1 0 | a Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. |
264 | 1 | c 2017 |
338 | a print2 rdacarrier | |
500 | a Collaborator Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. | |
520 | a BACKGROUND: Bioresorbable vascular scaffolds were developed to overcome the shortcomings of drug-eluting stents in percutaneous coronary intervention (PCI). We performed an investigator-initiated, randomized trial to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in the context of routine clinical practice.METHODS: We randomly assigned 1845 patients undergoing PCI to receive either a bioresorbable vascular scaffold (924 patients) or a metallic stent (921 patients). The primary end point was target-vessel failure (a composite of cardiac death, target-vessel myocardial infarction, or target-vessel revascularization). The data and safety monitoring board recommended early reporting of the study results because of safety concerns. This report provides descriptive information on end-point events.RESULTS: The median follow-up was 707 days. Target-vessel failure occurred in 105 patients in the scaffold group and in 94 patients in the stent group (2-year cumulative event rates, 11.7% and 10.7%, respectively; hazard ratio, 1.12; 95% confidence interval [CI], 0.85 to 1.48; P=0.43); event rates were based on Kaplan-Meier estimates in time-to-event analyses. Cardiac death occurred in 18 patients in the scaffold group and in 23 patients in the stent group (2-year cumulative event rates, 2.0% and 2.7%, respectively), target-vessel myocardial infarction occurred in 48 patients in the scaffold group and in 30 patients in the stent group (2-year cumulative event rates, 5.5% and 3.2%), and target-vessel revascularization occurred in 76 patients in the scaffold group and in 65 patients in the stent group (2-year cumulative event rates, 8.7% and 7.5%). Definite or probable device thrombosis occurred in 31 patients in the scaffold group as compared with 8 patients in the stent group (2-year cumulative event rates, 3.5% vs. 0.9%; hazard ratio, 3.87; 95% CI, 1.78 to 8.42; P<0.001).CONCLUSIONS: In this preliminary report of a trial involving patients undergoing PCI, there was no significant difference in the rate of target-vessel failure between the patients who received a bioresorbable scaffold and the patients who received a metallic stent. The bioresorbable scaffold was associated with a higher incidence of device thrombosis than the metallic stent through 2 years of follow-up. (Funded by Abbott Vascular; AIDA ClinicalTrials.gov number, NCT01858077 .). | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
700 | 1 | a Kraak, Robin P4 aut |
700 | 1 | a Hofma, Sjoerd H4 aut |
700 | 1 | a van der Schaaf, Rene J4 aut |
700 | 1 | a Arkenbout, E Karin4 aut |
700 | 1 | a IJsselmuiden, Alexander J4 aut |
700 | 1 | a Elias, Joëlle4 aut |
700 | 1 | a van Dongen, Ivo M4 aut |
700 | 1 | a Tijssen, Ruben Y G4 aut |
700 | 1 | a Koch, Karel T4 aut |
700 | 1 | a Baan, Jan4 aut |
700 | 1 | a Vis, M Marije4 aut |
700 | 1 | a de Winter, Robbert J4 aut |
700 | 1 | a Piek, Jan J4 aut |
700 | 1 | a Tijssen, Jan G P4 aut |
700 | 1 | a Henriques, Jose P S4 aut |
700 | 1 | a James, Stefanu Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)0 (Swepub:uu)stjam367 |
710 | 2 | a Uppsala universitetb Institutionen för medicinska vetenskaper4 org |
773 | 0 | t New England Journal of Medicineg 376:24, s. 2319-2328q 376:24<2319-2328x 0028-4793x 1533-4406 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-342873 |
856 | 4 8 | u https://doi.org/10.1056/NEJMoa1614954 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy